Patent EA-003216-B1 (EA)
Title: Use of 3-(1h-imidazol-4-ylmethyl)-indan-5-ol in the manufacture of a medicament for intraspinal, intrathecal or epidural administration
Inventor: HAAPALINNA ANTTI
IPC: A61K31/416
Filed: 1999-09-27
Abstract: 1. Use of 3-(1H-imidazol-4-ylmethyl)indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof in the manufacture of a medicament for intraspinal administration. 2. Use according to Claim 1, wherein the drug is 3-(1H-imidazol-4-ylmethyl)indan-5-of hydrochloride. 3. Use according to Claim 1, wherein the drug is administered intrathecally. 4. Use according to Claim 1, wherein the drug is administered epidurally. 5. Use according to any one of Claims 1-4, wherein the drug is administered to a human in an amount of from about 30 to 500 mug/patient. 6. Use according to Claim 5 to obtain analgesia. 7. Use according to Claim 5 as an adjunct to anaesthesia. 8. A method for obtaining analgesia, comprising administering to a mammal in need thereof an effective amount of 3-(1H-imidazol-4-ylmethyl)indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof intraspinally. 9. The method according to Claim 8, wherein 3-(1H-imidazol-4-ylmethyl)-indan-5-ol hydrochloride is administered. 10. The method according to Claim 8, wherein 3-(1H-imidazol-4-ylmethyl)-indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof is administered intrathecally. 11. The method according to Claim 8, wherein 3-(1H-imidazol-4-ylmethyl)indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof is administered epidurally. 12. The method according to any one of Claims 8-11, wherein the mammal is a human. 13. The method according to Claim 12, wherein the effective amount administered is from about 30 to 500 mug/patient. 14. The method according to Claim 13, wherein the effective amount administered is from about 50 to 200 mug/patient. 15. The method according to any one of Claims 8-11, wherein the mammal is a small mammal. 16. The method according to Claim 15, wherein the effective amount administered is from about 1 to 100 mug/patient. 17. The method according to Claim 16, wherein the small mammal is a dog or a cat. 18. The method according to Claim 17, wherein the effective amount administered is from about 3 to 30 mug/patient. 19. The method according to Claim 18, wherein the small mammal is a dog or a cat. 20. A method of using 3-(1H-imidazol-4-ylmethyl)indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof as an adjunct to anesthesia, comprising administering to a mammal in need thereof an effective amount of the drug intraspinally. 21. The method according to Claim 20, wherein 3-(1H-imidazol-4-ylmethyl)-indan-5-ol hydrochloride is administered. 22. The method according to Claim 20, wherein 3-(1H-imidazol-4-ylmethyl)indan-5-ol or a pharmaceutically acceptable ester or salt thereof is administered intrathecally. 23. The method according to Claim 20, wherein 3-(1H-imidazol-4-ylmethyl)indan-5-ol or a pharmaceutically acceptable ester or salt thereof is administered epidurally. 24. The method according to any one of Claims 20-23, wherein the mammal is a human. 25. The method according to Claim 24, wherein the effective amount administered is from about 30 to 500 mug/patient. 26. The method according to Claim 25, wherein the effective amount administered is from about 50 to 200 mug/patient. 27. A method for treating a mammal with 3-(1H-imidazol-4-ylmethyl)indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof, wherein the method comprises administering the drug to the mammal intraspinally for a time period sufficient to give the therapeutic effect. 28. The method according to Claim 27, wherein the mammal is a human. 29. The method according to Claim 27, wherein 3-(1H-imidazol-4-ylmethyl)indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof is administered intrathecally. 30. The method according to Claim 27, wherein 3-(1H-imidazol-4-ylmethyl)indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof is administered epidurally. 31. The method according to any one of Claims 27-30, wherein 3-(1H-imidazol-4-ylmethyl)-indan-5-ol hydrochloride is administered. 32. The method according to Claim 31, wherein intraoperative pain is treated. 33. The method according to Claim 31, wherein postoperative pain is treated. 34. The method according to Claim 31, wherein obstetric pain is treated. 35. The method according to Claim 31, wherein chronic pain is treated. 36. The method according to Claim 31, wherein spastic paraplegia is treated.